Literature DB >> 25187272

NF-κB, an active player in human cancers.

Yifeng Xia1, Shen Shen1, Inder M Verma2.   

Abstract

NF-κB comprises a family of five transcription factors that form distinct protein complexes, which bind to consensus DNA sequences at promoter regions of responsive genes regulating cellular processes. The past three decades have witnessed remarkable progress in understanding the NF-κB signaling pathway in physiologic and pathologic conditions. The role of NF-κB in human cancer initiation, development, metastasis, and resistance to treatment has drawn particular attention. A significant number of human cancers have constitutive NF-κB activity due to the inflammatory microenvironment and various oncogenic mutations. NF-κB activity not only promotes tumor cells' proliferation, suppresses apoptosis, and attracts angiogenesis, but it also induces epithelial-mesenchymal transition, which facilitates distant metastasis. In certain circumstances, NF-κB activation may also remodel local metabolism and anergize the immune system to favor tumor growth. Suppression of NF-κB in myeloid cells or tumor cells usually leads to tumor regression, which makes the NF-κB pathway a promising therapeutic target. However, because of its vital role in various biologic activities, components of the NF-κB pathway need to be carefully selected and evaluated to design targeted therapies. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25187272      PMCID: PMC4155602          DOI: 10.1158/2326-6066.CIR-14-0112

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  67 in total

Review 1.  Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel.

Authors:  T D Gilmore
Journal:  Oncogene       Date:  1999-11-22       Impact factor: 9.867

2.  Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma.

Authors:  Krishna P L Bhat; Veerakumar Balasubramaniyan; Brian Vaillant; Ravesanker Ezhilarasan; Howard Colman; Erik P Sulman; Kenneth Aldape; Karlijn Hummelink; Faith Hollingsworth; Khalida Wani; Lindsey Heathcock; Johanna D James; Lindsey D Goodman; Siobhan Conroy; Lihong Long; Nina Lelic; Suzhen Wang; Joy Gumin; Divya Raj; Yoshinori Kodama; Aditya Raghunathan; Adriana Olar; Kaushal Joshi; Christopher E Pelloski; Amy Heimberger; Se Hoon Kim; Daniel P Cahill; Ganesh Rao; Wilfred F A Den Dunnen; Hendrikus W G M Boddeke; Heidi S Phillips; Ichiro Nakano; Frederick F Lang
Journal:  Cancer Cell       Date:  2013-08-29       Impact factor: 31.743

3.  Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

Authors:  J C Cusack; R Liu; M Houston; K Abendroth; P J Elliott; J Adams; A S Baldwin
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 12.701

4.  Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3.

Authors:  Michael Martin; Kunal Rehani; Richard S Jope; Suzanne M Michalek
Journal:  Nat Immunol       Date:  2005-07-10       Impact factor: 25.606

5.  Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases.

Authors:  Hideaki Kamata; Shi-Ichi Honda; Shin Maeda; Lufen Chang; Hajime Hirata; Michael Karin
Journal:  Cell       Date:  2005-03-11       Impact factor: 41.582

6.  GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB.

Authors:  Deepali Bang; Willie Wilson; Meagan Ryan; Jen Jen Yeh; Albert S Baldwin
Journal:  Cancer Discov       Date:  2013-04-01       Impact factor: 39.397

7.  p53 recruitment of CREB binding protein mediated through phosphorylated CREB: a novel pathway of tumor suppressor regulation.

Authors:  H A Giebler; I Lemasson; J K Nyborg
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

8.  IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis.

Authors:  Shin Maeda; Hideaki Kamata; Jun-Li Luo; Hyam Leffert; Michael Karin
Journal:  Cell       Date:  2005-07-01       Impact factor: 41.582

9.  Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer.

Authors:  Tomer Cooks; Ioannis S Pateras; Ohad Tarcic; Hilla Solomon; Aaron J Schetter; Sylvia Wilder; Guillermina Lozano; Eli Pikarsky; Tim Forshew; Nitzan Rosenfeld; Nitzan Rozenfeld; Noam Harpaz; Steven Itzkowitz; Curtis C Harris; Varda Rotter; Vassilis G Gorgoulis; Moshe Oren
Journal:  Cancer Cell       Date:  2013-05-13       Impact factor: 31.743

10.  Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma.

Authors:  Wen Xue; Etienne Meylan; Trudy G Oliver; David M Feldser; Monte M Winslow; Roderick Bronson; Tyler Jacks
Journal:  Cancer Discov       Date:  2011-06-16       Impact factor: 39.397

View more
  360 in total

1.  SNW1, a Novel Transcriptional Regulator of the NF-κB Pathway.

Authors:  Suneer Verma; Paul De Jesus; Sumit K Chanda; Inder M Verma
Journal:  Mol Cell Biol       Date:  2019-01-16       Impact factor: 4.272

2.  Inhibition of cell-intrinsic NF-κB activity and metastatic abilities of breast cancer by aloe-emodin and emodic-acid isolated from Asphodelus microcarpus.

Authors:  Amira A Abdellatef; Moustafa Fathy; Abd El-Salam I Mohammed; Marwa S Abu Bakr; Amal H Ahmed; Hatem S Abbass; Ahmed H El-Desoky; Hiroyuki Morita; Toshio Nikaido; Yoshihiro Hayakawa
Journal:  J Nat Med       Date:  2021-05-14       Impact factor: 2.343

3.  MALT1 is a critical mediator of PAR1-driven NF-κB activation and metastasis in multiple tumor types.

Authors:  Peter C Lucas; Linda M McAllister-Lucas; J Randall McAuley; Kelly M Bailey; Prasanna Ekambaram; Linda R Klei; Heejae Kang; Dong Hu; Tanner J Freeman; Vincent J Concel; Nathaniel E Hubel; Jia-Ying Lloyd Lee; Hanna B Klei; Jing Cheng; Preethiya Sekar; Rachel E Bridwell; Lidija Covic
Journal:  Oncogene       Date:  2019-08-16       Impact factor: 9.867

4.  MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer.

Authors:  Mengyu Xie; Hong Zheng; Ranjna Madan-Lala; Wenjie Dai; Nicholas T Gimbrone; Zhihua Chen; Fumi Kinose; Sarah A Blackstone; Keiran S M Smalley; W Douglas Cress; Eric B Haura; Uwe Rix; Amer A Beg
Journal:  Cancer Res       Date:  2019-07-30       Impact factor: 12.701

5.  Lung Adenocarcinoma Syndecan-2 Potentiates Cell Invasiveness.

Authors:  Konstantin Tsoyi; Juan C Osorio; Sarah G Chu; Isis E Fernandez; Sergio Poli De Frias; Lynette Sholl; Ye Cui; Carmen S Tellez; Jill M Siegfried; Steven A Belinsky; Mark A Perrella; Souheil El-Chemaly; Ivan O Rosas
Journal:  Am J Respir Cell Mol Biol       Date:  2019-06       Impact factor: 6.914

Review 6.  miRNA-223 at the crossroads of inflammation and cancer.

Authors:  Jacob Jeffries; Wenqing Zhou; Alan Y Hsu; Qing Deng
Journal:  Cancer Lett       Date:  2019-03-13       Impact factor: 8.679

Review 7.  Ca2+ as a therapeutic target in cancer.

Authors:  Scott Gross; Pranava Mallu; Hinal Joshi; Bryant Schultz; Christina Go; Jonathan Soboloff
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

Review 8.  p21-Activated Kinases in Thyroid Cancer.

Authors:  Luis Bautista; Christina M Knippler; Matthew D Ringel
Journal:  Endocrinology       Date:  2020-08-01       Impact factor: 4.736

Review 9.  Circulating tumor cell interactions with macrophages: implications for biology and treatment.

Authors:  Gerhard Hamilton; Barbara Rath
Journal:  Transl Lung Cancer Res       Date:  2017-08

Review 10.  Improving Diagnostic and Therapeutic Outcomes in Pediatric Brain Tumors.

Authors:  Sydney T Grob; Jean M Mulcahy Levy
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.